Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Moasser

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Advances in Cancer Research|June 29, 2020
HER family in cancer progression: From discovery to 2020 and beyondRakesh Kumar, Bijesh George, Marcia R Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancerA Jo Chien, Pamela N Munster, Michelle E Melisko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Cell Reports|February 2, 2022
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancersMarcia R Campbell, Ana Ruiz-Saenz, Elliott Peterson, et al.
Biochemical Pharmacology|November 5, 2020
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin ASoheila Kazemi, Shinsaku Kawaguchi, Christian E Badr, et al.
Cancer Research Communications|March 16, 2023
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor MalignanciesErica S Tsang, Rahul R Aggarwal, Mallika S Dhawan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 15, 2014
A multilevel model of postmenopausal breast cancer incidenceRobert A Hiatt, Travis C Porco, Fengchen Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2017
CD318 is a ligand for CD6Gospel Enyindah-Asonye, Yan Li, Jeffrey H Ruth, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Advances in Cancer Research|June 29, 2020
HER family in cancer progression: From discovery to 2020 and beyondRakesh Kumar, Bijesh George, Marcia R Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2014
Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancerA Jo Chien, Pamela N Munster, Michelle E Melisko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatmentsChau T Dang, Andrew J Dannenberg, Kotha Subbaramaiah, et al.
Clinical Breast Cancer|May 19, 2005
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi, Violante E Currie, Andrew D Seidman, et al.
Cell Reports|February 2, 2022
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancersMarcia R Campbell, Ana Ruiz-Saenz, Elliott Peterson, et al.
Biochemical Pharmacology|November 5, 2020
Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin ASoheila Kazemi, Shinsaku Kawaguchi, Christian E Badr, et al.
Cancer Research Communications|March 16, 2023
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor MalignanciesErica S Tsang, Rahul R Aggarwal, Mallika S Dhawan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 15, 2014
A multilevel model of postmenopausal breast cancer incidenceRobert A Hiatt, Travis C Porco, Fengchen Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 2, 2017
CD318 is a ligand for CD6Gospel Enyindah-Asonye, Yan Li, Jeffrey H Ruth, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Pageof 6